Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2022-10-30 Annual Report
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Annual Report (Typeset) 78 pages 3.5MB
Annual Report Classification · 100% confidence The document is titled '2022 Annual Report For the Year Ended 30th June 2022' and contains detailed sections typical of an annual report, including Directors' Report, Auditor's Independence Declaration, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, and Independent Audit Report. It includes comprehensive financial data, operational review, corporate directory, and auditor information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content and structure align with the definition of an Annual Report (10-K). FY 2022
2022-10-30 English
Notice of Annual General Meeting/Proxy Form 41 pages 1.2MB
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) and Proxy Form for Neurotech International Limited, dated 31 October 2022, for the AGM scheduled on 30 November 2022. It includes details about the meeting logistics, agenda items such as receiving the Annual Report, adoption of the Remuneration Report, election and re-election of directors, and shareholder resolutions on share issuance and options. The document is a formal notice and proxy solicitation for the AGM, not the actual Annual Report or other financial statements. It is a communication sent to shareholders to inform them about the meeting and solicit their votes, which fits the definition of AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is the meeting notice and proxy form, not a report publication announcement or regulatory filing. Therefore, the correct classification is AGM Information (AGM-R).
2022-10-30 English
Neurotech Completes $9.0M Placement 3 pages 283.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 October 2022 regarding a $9.0 million share placement by Neurotech International Limited. It details the share placement terms, use of funds, and clinical trial progress but does not contain financial statements or detailed financial performance data. The focus is on capital raising and financing activities, including share issuance and options. The document length is 8058 characters, which is substantive but the content is clearly about a capital raise rather than a full financial report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2022-10-27 English
Proposed issue of securities - NTI 8 pages 36.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Neurotech International Limited regarding a proposed issue of securities, including placements of ordinary shares and options. It details the number of securities to be issued, issue prices, conditions, fees, and the purpose of the capital raise. The document is structured as a formal announcement to the ASX (Australian Securities Exchange) about a capital raising event. It does not contain financial statements, earnings data, or management discussion of financial results. Instead, it focuses on the issuance of new securities and related terms. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief notice or a simple report publication announcement, but a substantive update on financing activities.
2022-10-27 English
Investor Presentation 32 pages 2.1MB
Investor Presentation Classification · 95% confidence The document is titled 'Phase I/II ASD 20 Week Results & Capital Raise: Investor Presentation' and is dated 26 October 2022. It contains detailed clinical trial results for a Phase I/II study on Autism Spectrum Disorder (ASD), including safety and efficacy data over 20 weeks, statistical analysis, and clinical interpretations. The document also includes a section on capital outlook and raise, indicating financing activities. The content is structured as a presentation with slides, disclaimers, and forward-looking statements, typical of investor presentations. There is no indication that this is a full annual or interim financial report, audit report, or regulatory filing. The presence of detailed clinical trial results combined with capital raise information aligns with the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content confirm it is the presentation itself, not merely an announcement or summary. Therefore, the appropriate classification is Investor Presentation (IP).
2022-10-27 English
Reinstatement to Quotation 1 page 418.6KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement to quotation of Neurotech International Limited's securities following a capital raise announcement. It is a short notice about trading suspension being lifted, not a detailed financial report or capital raise update itself. It does not contain financial data or detailed capital structure changes, but rather a regulatory announcement about trading status. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2022-10-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.